Immunotherapy News and Research

Latest Immunotherapy News and Research

Exploring AI’s impact on precision oncology

A new editorial was published in Oncotarget's Volume 15 on August 26, 2024, entitled, "Artificial intelligence: A transformative tool in precision oncology."

27 Aug 2024

$120 million gift boosts UCLA’s efforts in immunotherapy and innovation

UCLA has received a $120 million commitment from surgeon, inventor and philanthropist Dr. Gary Michelson and his wife, Alya, to kick-start the California Institute for Immunology and Immunotherapy, an innovative public-private partnership aimed at spurring breakthrough discoveries that prevent and cure diseases and catalyze economic growth and innovation in Los Angeles.

27 Aug 2024

Common chemotherapy supplement weakens the pancreatic cancer's defenses in mice

The fight against cancer is an arms race, and one of the most effective weapons in clinicians' arsenals is immunotherapy. Immune checkpoint therapy has become the standard for treating several types of cancer.

27 Aug 2024

UQ study unlocks potential for advanced bladder cancer immunotherapy

University of Queensland research could lead to a more effective immunotherapy treatment against bladder cancer.

27 Aug 2024

Study reveals metabolic switch crucial for memory T cell formation and cancer immunity

A Ludwig Cancer Research study has identified a metabolic switch in the immune system's T cells that is essential to the generation of memory T cells-;which confer lasting immunity to previously encountered pathogens-;and a T cell subtype found in tumors that drives anti-tumor responses during immunotherapy.

23 Aug 2024

Multimodal therapy shows promise for cancer treatment

Cancer remains one of the most challenging diseases to treat due to its complexity and tendency to metastasize (spread into or invade, nearby tissues or distant places in the body to form new tumors). Traditional therapies, such as chemotherapy and radiation, often face limitations like non-specific targeting and severe side effects. In response, researchers are turning to innovative approaches that combine multiple therapeutic modalities to address these issues. This study explores a cutting-edge solution involving CNHs to create a multimodal cancer phototheranostic platform integrating photothermal therapy (PTT), immunotherapy, and chemotherapy.

23 Aug 2024

Advancing cancer therapy with small molecule immune checkpoint inhibitors

Immunotherapy has revolutionized cancer treatment, with immune checkpoint inhibitors (ICIs) playing a pivotal role.

21 Aug 2024

UQ research could lead to a more effective treatment for bladder cancer

University of Queensland research could lead to a more effective immunotherapy treatment against bladder cancer.

20 Aug 2024

Advances in precision medicine enhance cancer immunotherapy

The field of precision medicine, especially in the context of cancer immunotherapy, has seen significant advancements in recent years.

20 Aug 2024

New project aims to study the combination of two therapies for pediatric brain cancer

Natasha Sheybani, assistant professor of biomedical engineering at the University of Virginia School of Engineering, will collaborate with researchers at Children's National Hospital to study the combination of two therapies for pediatric brain cancer.

19 Aug 2024

Advancements in neoantigen vaccines offer hope for personalized cancer therapy

The saga of cancer treatment is marked by a relentless pursuit of effectiveness against a disease characterized by complexity and adaptability.

19 Aug 2024

Ribonucleic acid for injection II enhances immunity and hematopoiesis in immunosuppressed mice

Announcing a new publication for Acta Materia Medica journal. Ribonucleic acid for injection II is a clinical adjuvant cancer therapy treatment based on immunotherapy, which exerts its effects by enhancing immune function and suppressing tumor growth.

16 Aug 2024

Neoadjuvant immunotherapy yields comparable outcomes in high-risk liver cancer surgery

Patients with liver cancer who received immune checkpoint inhibitors (ICIs) before surgery-;including those who would not have been eligible for surgery by conventional criteria-;had similar outcomes to patients who received surgery upfront, according to results from a retrospective study.

15 Aug 2024

New trial explores BAFF CAR T-cell therapy for relapsed myeloma

University Hospitals (UH) Seidman Cancer Center hematologist-oncologist Leland Metheny, MD, is leading the trial.

14 Aug 2024

New targets for improved cancer immunotherapy

In the past two decades, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, showing promising results against various solid tumors. This study reviews recent developments in ICIs, focusing on new targets like T cell immunoreceptors with Ig and ITIM domains (TIGIT), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), and lymphocyte activation gene-3 (LAG-3). These targets aim to overcome resistance mechanisms limiting the effectiveness of current therapies, such as anti-PD-1 and anti-CTLA-4. By identifying and developing these new ICIs, researchers hope to improve treatment outcomes and provide new therapeutic options for cancer patients.

14 Aug 2024